Background: The role of insulin resistance (IR) in the pathogenesis of cognitive performance is not yet clear. Objective: To examine the associations between IR and cognitive performance and change in cognitive functions two decades later in individuals with cardiovascular disease with and without diabetes. Methods: A subset of 489 surviving patients (mean age at baseline 57.7 ± 6.5 y) with coronary heart disease who previously participated in the secondary prevention Bezafibrate Infarction Prevention (BIP trial; 1990-1997, were included in the current neurocognitive study. Biochemical parameters including IR (using the homeostasis model of assessment; HOMA-IR) were measured at baseline. During 2004-2008, computerized cognitive assessment and atherosclerosis parameters were measured (T1; n = 558; mean age 72.6 ± 6.4 years). A second cognitive assessment was performed during 2011-2013 (T2; n = 351; mean age 77.2 ± 6.4 years). Cognitive function, overall and in specific domains, was assessed. We used linear regression models and linear mixed models to evaluate the differences in cognitive performance and decline, respectively. Results: Controlling for potential confounders, IR (top HOMA-IR quartile versus others) was associated with subsequent poorer cognitive performance overall (␤ = -4.45 ± Standard Error (SE) 1.54; p = 0.004) and on tests of memory and executive function among non-diabetic patients (␤ = -7.16 ± 2.38; p = 0.003 and ␤ = -3.33 ± 1.84; p = 0.073, respectively). Moreover, among non-diabetic patients, IR was related to a greater decline overall (␤ = -0.17 ± 0.06; p = 0.008), and in memory (␤ = -0.22 ± 0.10; p = 0.024) and executive function (␤ = -0.19 ± 0.08; p = 0.012). The observed associations did not differ after excluding subjects with prevalent stroke or dementia. Conclusion: IR is related to subsequent poorer cognitive performance and greater cognitive decline among patients with cardiovascular disease with and without diabetes.
INTRODUCTION
Life expectancy is rising, placing individuals at risk to develop cognitive impairment [1] . Elderly patients with cardiovascular disease are particularly prone to develop cognitive decline and dementia [2] . There is growing body of evidence suggesting that most dementia cases involve both vascular and neurodegenerative pathologies [3, 4] .
Diabetes is associated with an increased risk of cognitive impairment [5] [6] [7] and ischemic cerebrovascular events [8, 9] . Insulin regulates synaptic plasticity and activity in the cortex and hippocampus, brain regions generally associated with learning and memory [10, 11] . Moreover, hippocampal insulin resistance (IR) can cause the development of structural and functional deficits and thus increase the risk of cognitive impairment and dementia among diabetic patients [12] . In healthy individuals, the relationship between IR and cognitive function is inconclusive [13] [14] [15] [16] [17] [18] [19] [20] [21] with only few studies evaluating the longitudinal association between IR and cognitive decline [13] [14] [15] [16] [17] . To our knowledge, this association has not been systematically tested among individuals with cardiovascular disease, who have a large vascular burden and therefore are prone to cognitive impairment. The purpose of the current study was to examine the associations between IR and cognitive performance and change in cognitive functions two decades later in individuals with cardiovascular disease with and without diabetes.
MATERIALS AND METHODS

Participants
The study sample includes individuals who previously participated in the Bezafibrate Infarction Prevention (BIP) clinical trial of lipid modification who were recruited from 8 central hospitals (n = 1,232) and reside in the central region of Israel. The BIP trial was a large multi-center, placebocontrolled randomized clinical trial investigating the efficacy of bezafibrate 400 mg daily, a fibric derivative, in secondary prevention among participants with established stable coronary heart disease [22] . Participants were recruited from 18 centers in Israel between 1990-1992 and included men and women 45 to 74 years of age with a history of myocardial infarction at least 6 months and no longer than 5 years before enrollment and/or stable angina pectoris during the last 2 years confirmed by coronary angiography, and/or radionuclide studies or standard exercise tests. The lipid profile of participants at inclusion was as follows: serum total cholesterol 180 to 250 mg/dL, low-density lipoprotein-cholesterol ≤180 mg/dL (≤160 mg/dL for people <50 years), high-density lipoprotein-cholesterol ≤45 mg/dL, and triglycerides ≤300 mg/dL. Other exclusion criteria were insulin-dependent diabetes, hepatic or renal failure, and disabling stroke.
Baseline laboratory measurements
Blood samples were drawn from each study participant at baseline of the BIP trial (1990-1992), before randomization. Samples were collected after at least 12 hours of fasting, with the use of standardized equipment and procedures and transferred to a central study laboratory. Plasma citrate samples, which had been taken at baseline from each study participant and stored at -70 • C, were thawed and assayed for insulin level by Immulite 2000 analyzer (Diagnostic Products Corporation, Los Angeles, CA) with manufacturer's reagents-solidphase, two-site, chemiluminescent enzyme-labeled immunometric assay. This assay uses monoclonal and polyclonal antibodies for the capture and detection, respectively, of insulin. The inter-and intra-observer variability of the insulin test in our study was 6.1% and 7.9%, respectively.
IR was defined as Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) in the top quartile. HOMA-IR was calculated according to the homeostasis model of assessment as follows fasting insulin (U/ml) × fasting glucose (mg/dl)/405. C reactive protein concentrations were measured in samples of citrated plasma stored at -70 • C for ∼12 years with the use of standard automated procedures with commercially available kits (Roche Diagnostics). Precipitation of low-density lipoprotein (LDL) and VLDL with phosphotungstate reagent and determination of cholesterol determined high-density lipoprotein (HDL) cholesterol. Total cholesterol was determined by the CHOD-PAP method (enzymatic colorimetric test) and LDL cholesterol approximated by the Friedewald formula.
Diabetes was defined based on the reported history and medical records. In addition, in accordance with the American Diabetes Association classification, all patients with fasting blood glucose ≥126 mg/dL or who were prescribed with anti-diabetic treatment were classified as diabetics. Heart failure functional class was classified according to the New York Heart Association (NYHA) classification [23] . According to this classification, class I indicates no limitation, whereas class IV indicates inability to carry on any physical activity without discomfort. Education, occupation, and place of birth, important indicators of socioeconomic status, were assessed through a baseline questionnaire. We included data on birth place, which is an important key indicator of socioeconomic status disparities and possibly of genetic predisposition. In addition, previous studies suggest that risk of cognitive impairment differs between Israeli-born and immigrants populations [24, 25] . Physical activity was assessed by asking participants "Do you participate in one or more of the following activities such as walking, swimming, jogging, gymnastics, biking, dancing, tennis, gardening and rehabilitation activities" and "How many times per week do you engage in physical activity". Comorbidity at baseline included non-disabling stroke, myocardial infarction, chronic kidney disease, chronic obstructive pulmonary disorder, and peripheral artery disease. Subjects were classified into either low comorbidity defined as none or one of the diseases or into high comorbidity defined as two or more diseases.
Late-life evaluations
Participants who survived by 2004 were invited to participate in the BIP Neurocognitive Study. The first evaluation was performed between 2004 and 2009 (T1), an average of 15 ± 3 years after the baseline evaluation. Between 2011 and 2013, patients were reassessed (T2). The mean time interval between the two cognitive assessments was 4.8 ± 1.3 years. The two late-life evaluations took place at a central research center (the Sagol Neuroscience Center), or if unable or unwilling to attend the medical center, were assessed at their residence. In both evaluations, data were collected systematically regarding new co-morbidities and hospitalizations, medication use, smoking status, physical activity, and anthropometric measurements. The study was approved by the local institutional review board and informed consent was obtained from participants.
Cognitive assessment
Participants completed the NeuroTrax computerized cognitive testing (NeuroTrax Corp., Bellaire, TX). A description of the tests included has been published elsewhere [26] . The psychometric properties of the tests exploit the advantages of computerized testing, providing precise accuracy and reaction time measurements. The tests are interactive and adaptive, adjusting the level of difficulty depending upon performance, and are designed for use with the elderly. Guidance and feedback were provided in the brief practice sessions that precede each test, but not during the actual tests. All responses were made using the mouse buttons or with the number pad on the keyboard. The Neurotrax software calculates raw composite scores for each cognitive domain, namely: memory, executive function, visual spatial processing, and attention. In addition, a composite score was computed as a weighted average of all summary scores from each domain. All scores are then normalized according to age-and education-specific normative data and scaled to an IQ-style scale with mean of 100 and SD of 15. Cognitive impairment was defined as cognitive performance ≤85 on the normalized scale (1SD below the mean). Dementia and incident stroke during follow-up were determined by an adjudication committee composed of three investigators, two of which are experienced board certified neurologists. Dementia was determined in accordance with the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria [27] . Stroke was defined according to the World Health Organization criteria [28] .
Ultrasound indices of cerebrovascular disease
Participants underwent an ultrasound-based evaluation for assessing cerebral large vessel atherosclerosis and cerebral small vessel occlusive disease. Common carotid intima-media thickness (CC-IMT) was measured at the far wall of both common carotid arteries using high resolution B-mode ultrasound. Assessment followed a standard protocol that included acquiring images of both carotid arteries and measurement thickness employing automatic edge detection (Metris, Argenteuil, France) and presence or absence of carotid plaques. The breath-holding index was used to assess cerebrovascular reactivity, a marker of cerebral microvascular dysfunction, by transcranial Doppler (Rimed Trans-link 9900 TCD, Herzliya, Israel) [29] . Mean flow velocity at rest was obtained by continuous recording over a 1-minute period of normal breathing. Participants were asked to hold their breath for 30 seconds or as long as possible. The exact length of apnea was mea-sured. Before proceeding to the definitive recording, subjects were trained to perform the procedure correctly. The breath-holding index was calculated as: [(Vbh-Vr)/Vr] 100 /s), where Vbh is mean flow velocity at the end of breath-holding, Vr the mean flow velocity at rest, and s is seconds of breathholding.
Data analyses
Patients were categorized into quartiles of baseline HOMA-IR, with cut-off points at ≤0.65, 0.66-1.10, 1.11-1.59, and ≥1.60 (0.36 ± 0.2, 0.87 ± 0.1, 1.34 ± 0.1 and 2.65 ± 1.5, mean ± sd, respectively). We detected a threshold in the association between HOMA-IR quartiles and cognitive scores, and accordingly compared the top HOMA-IR quartile to the other quartiles. Due to non-normal HOMA-IR distribution, natural logarithm (ln)-transformed baseline HOMA-IR were used.
The clinical characteristics of the participants are expressed as percentages and as mean ± SD, except when the distribution was strongly skewed, in which case, median and interquartile range are provided. Chi-square and t-tests were performed in order to compare the baseline characteristics of people in the two IR groups. Differences between the IR groups in cognitive performance at the first late-life evaluation were assessed using linear regression models. We used linear mixed-effect models to assess the relationship between IR groups and change in cognitive performance. Follow-up time was included in the mixed-effect models as a random effect to represent the within-study variability in time between T1 and T2 assessments in years. Additionally, all models included time and the interaction of age and time.
Attention scores were transformed to the power of 4 in order to meet normal distribution. For the purpose of assessing the relationship between IR groups and cognitive scores at the first late-life evaluation, we used the normalized scores from the Neurotrax battery. However, because normalization was done according to age within categories of 5 years, it was not suitable for use in the longitudinal analysis. Using normalized score in both the first and the second late-life evaluations would have caused bias since individuals differ in the way they toggle between age categories when moving from the first to the second late-life evaluations. Therefore, in order to assess change in cognition, we computed z-scores from the raw scores.
Adjustment was made first for age, sex, and education and additionally for birth place, height, smoking, body mass index, angina pectoris, co morbidity, depressive symptoms, and study arm. We added data of ultrasound indices of cerebrovascular disease inorder to examine whether associations between IR and cognitive impairment and decline were modified through the extent of vascular disease.
We also performed the following sensitivity analyses: 1) excluding participants who had prevalent diabetes at the time of the cognitive evaluations, 2) excluding participants with prevalent stroke and dementia at time of the cognitive evaluation, and 3) excluding women (5% of the sample).
Statistical significance was assessed for multiple comparisons, using the False Discovery Rate method with the p-value threshold of 0.03 [30] . Because of loss to follow up of eligible subjects who had either died or refused to participate, we used an adaptation of a marginal structural model applying inverse probability weights [31] . We estimated the probability of every individual to actually reach the first and second cognitive assessments. We then compared the results of weighted analysis with non-weighted analysis. Data were analyzed using SPSS version 21 (SPSS Inc., Chicago, IL).
RESULTS
Of the 1,232 individuals eligible for the late-life evaluation, 214 had died, 259 refused to participate, 102 could not be contacted, 45 were unable to participate due to dementia, language incompatibility, vision or hearing defects or physical disability, and 54 had missing data. This resulted in 558 people available for the first late-life assessment (T1) (Fig. 1) . Compared to 674 individuals who did not participate in the T1 evaluation, those included had a higher proportion of men to women (p < 0.001), and were younger (p < 0.001) and more educated (p < 0.001). In addition, participants included in T1 had lower systolic (130 ± 17.4 mmHg versus 134 ± 19 mmHg, p < 0.001) and diastolic blood pressure (81 ± 9.4 mmHg versus 82 ± 10 mmHg, p = 0.06), but had higher levels of total cholesterol (213 ± 17.6 mg/dl versus 211 ± 18 mg/dl, p = 0.01) and creatinine (1.11 ± 0.14 mg/dl versus 1.15 ± 0.14 mg/dl, p = 0.003) (Supplementary Table 1) .
Of 558 patients, complete information on cognitive and HOMA-IR measurements was available for 489 participants. Their mean age at T1 was 72.6 ± 6.4 and 95% were men. Table 1 presents their baseline characteristics according to IR categories. Individuals with IR had higher BMI (27.4, IQR: 25.6-29.7 versus 25.6 IQR: 24.3-27.5), higher systolic blood pressure (133 ± 18 versus 129 ± 18 mmHg), and were more likely to have co-morbidities (29.5% versus 18.5%). Also, high levels of HOMA-IR were associated with increased levels of C reactive protein (2.9, IQR: 1.9-5.6 versus 2.5 IQR: 1.5-4.5) and triglycerides (148, IQR: 117-188 versus 132.6 IQR: 102.1-177.4). A total of 363 patients were re-assessed at the second late-life evaluation (mean age 77 ± 6.4 y; Fig. 1 ) and 347 of them had HOMA-IR measurements as well as two cognitive evaluations. The attrition between the two cognitive evaluations was mainly due to interim death (n = 114), and in addition, 58 refused to participate, 4 could not be contacted, and 19 had missing data. Twenty-eight individuals had dementia and 54 individuals had strokes at T1, and additional 31 and 39 individuals at T2, respectively. One hundred and six individuals had diabetes at T1, and 160 developed diabetes between T1 and T2.
After adjustment for age, sex, and education, individuals with IR at baseline had poorer performance overall (␤ = -2.50 ± 1.09; p = 0.023), and in memory (␤ = -3.22 ± 1.53; p = 0.035) and executive function (␤ = -2.3 ± 1.4; p = 0.022) at the first late-life examination (Table 2) . After additional adjustment for potential risk factors and indices of cerebrovascular disease, these associations were not materially different for overall performance (␤ = -3.66 ± 1.24; p = 0.003), memory (␤ = -5.22 ± 1.85; p = 0.005), and executive function (␤ = -4.03 ± 1.47; p = 0.006) ( Table 2) . After excluding people with diabetes at the time of assessment, these associations remained statistically significant (␤ = -4.45 ± 1.54; p = 0.004, and ␤ = -7.16 ± 2.38; p = 0.003 for composite and memory scores, respectively) ( Table 4) .
Among those who were re-assessed, cognitive performance was significantly poorer in the second compared to the first assessment overall in all cognitive domains except for attention. The associations between IR and cognitive change in different domains are shown in Fig. 2 . After adjustment for age, sex, education, time, a term for the interaction between age and time, vascular risk factors, and cerebrovascular reactivity (CVR) the decline in overall cognitive performance composite z-score (␤ = -0.16 ± 0.06; p = 0.006) as well as memory (␤ = -0.23 ± 0.09; p = 0.010) and executive function (␤ = -0.19 ± 0.07; p = 0.011) was greater among individuals with IR at baseline (Table 3) . After excluding patients with diabetes at the time of the second cognitive assessment these association remained statistically significant (␤ = -0.17 ± 0.06; p = 0.008, and ␤ = -0.22 ± 0.10; p = 0.024, and ␤ = -0.19 ± 0.08; p = 0.012, for composite, memory and executive function scores, respectively) ( Table 4) .
We repeated the analysis using ln HOMA-IR at baseline as a continuous variable. A 1 point increment in the ln HOMA-IR was related to a poorer composite, executive function, and attention scores (␤ = -1.55 ± 0.61; p = 0.012, ␤ = -1.88 ± 0.72; p = 0.010, ␤ = -2.05 ± 0.86; p = 0.017, respectively) and to a larger decline in cognitive function (Table 5) . After excluding participants with prevalent stroke and dementia at time of the late-life evaluation, the associations between IR at baseline, with cognition and change in cognitive performance did not differ (Supplementary Tables 2 and 3 ). Assessing late-life cognitive impairments (cognitive score of ≤85) as an outcome variable, a 1 point increment in the ln HOMA-IR was associated with an adjusted OR of 1.35 (95% CI 1.07-1.71, p = 0.012) for composite score, OR of 1.36 (95% CI 1.08-1.72, p = 0.01) for impairment in executive function and OR of 1.37 (95% CI 1.08-1.73, p = 0.009) for impairment in attention (Supplementary Table 4) . In reanalysis applying inverse probability weighting, the associations between IR at baseline and cognitive performance yielded similar results. In addition, the results did not change after excluding the small number of women (data not tabulated). Table 3 Mean change in Z-scores of cognitive performance between 2 evaluations by insulin resistance group (upper versus other HOMA-IR quartiles); n = 347 
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DISCUSSION
In this cohort of people with cardiovascular disease, IR measured at mean age of 57.7 ± 6.5 years was related to subsequent late-life poorer cognitive performance as well as to a larger decline in cognitive function. This association was apparent in the overall assessed, as well as among individuals without diabetes at baseline or during follow-up. Specifically, higher baseline HOMA-IR levels were associated with poorer executive function and memory performance 15 years later and with cognitive decline over a further period of 5 years. These observed relationships were independent of vascular risk factors, and remained similar after excluding those with a history of stroke, dementia or diabetes.
None of the indices of cerebrovascular disease (CVR, CC-IMT, and carotid plaques) significantly mediated the associations between HOMA-IR and cognitive impairment or decline. Our findings thus indicate a possible non-vascular component for the cognitive decline. Age-related neurodegenerative lesions are present in most older individuals and traditionally associated with dementia, but are also found in the brains of old persons who died with mild or no cognitive impairment [32] . Our results are in line with prior evidence supporting the concept that IR is important in the pathogenesis of cognitive impairment and neurodegeneration [10] . We found that IR is related to cognitive decline twenty years after it was measured. Nevertheless, cognitive performance in previous studies was assessed mostly using brief or telephone-based cognitive evaluations [14, 15] . In women aged 30-55 without type 2 diabetes at baseline, higher levels of fasting insulin were associated with faster rates of late-life cognitive decline which was measured using the Telephone Interview for Cognitive Status (TICS test) [14] . In another study [13] , IR was associated with a greater decline over 6 years in delayed word recall and first letter word fluency scores among adults aged 45-64 years at baseline. Okereke et al. [15] reported that in non-diabetic men, aged 60-92 years at baseline, who participated in cognitive testing an average of 3.3 years later, higher fasting insulin was associated with a greater decline on the TICS test. Euser et al. [17] analyzed data from two independent prospective studies: the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) and the Rotterdam Study (mean age 75.3 ± 3.3 and 71.8 ± 6.6 years at baseline, respectively). In contrast to our findings, they did not find an association between IR in the absence of diabetes history and cognitive function or decline in MMSE performance over 10 years of follow-up [17] .
Unhealthy lifestyle, as well as genetic predisposition, may lead to IR and diabetes. Previously a disease of middle-aged and older adults, type 2 diabetes is rapidly increasing among young individuals, paralleling increasing rates of obesity [9] . Both diabetes and increased fasting blood glucose may be associated with reduced cognitive performance, greater brain atrophy, white matter hyperintensity volumes, and injury to white matter microstructure in young and middle-aged participants of the Framingham study [33] . There are growing biological evidence pointing to a role of insulin in the brain in the mechanisms underlying cognitive impairment [10] . First, in peripheral hyperinsulinemia, insulin transportation via the blood-brain barrier is reduced, leading to reduced levels of insulin in the brain. Insulin and its receptor are found in brain regions such as the hippocampus and frontal cortex which in turn are associated with memory and executive functioning [34] . In the brain, insulin binding to the receptor, which activates signaling cascades that are similar to those observed in peripheral tissues. Insulin signaling modulates neurotransmitter channel activity, brain cholesterol synthesis, and mitochondrial function. Disruption of insulin action in the brain leads to impairment of neuronal function and synaptogenesis [35] . Further, insulin may affect the metabolism of amyloid-␤ and tau, two proteins that represent the building blocks of amyloid plaques and neurofibrillary tangles [35, 36] . Lastly, IR is associated with inflammation and oxidative stress, which could directly affect neurons [37] . Diabetes has a long prodromal phase which allows greater opportunity for prevention and intervention [10] . Indeed, in a recent randomized clinical trial, the risk of incident myocardial infarction and diabetes, as well as of recurrent stroke was lower among diabetes-free subjects with a recent history of stroke/transient ischemic attack who received pioglitazone, which improves insulin sensitivity compared to placebo [38] . Furthermore, restoring insulin function in the brain via intranasal insulin is a potential therapeutic option for neurocognitive dysfunction in insulin resistance, diabetes, and dementia [10] .
Strengths of this study include a cohort of patients extensively investigated for traditional and novel vascular risk factors, the use of a validated computerized assessment tool to quantify cognitive function globally and in specific domains, and evaluation for ultrasound indices of cerebral small-vessel and largevessel disease. In addition, the fact that HOMA-IR was measured at an average of 15 years before T1 cognitive assessment has provided us an excellent opportunity to examine the longitudinal relationship between HOMA-IR on cognitive performance and cognitive decline. We excluded participants who were diagnosed with both baseline and interim diabetes, thus, excluding patients with undiagnosed diabetes at the time of HOMA-IR measurement. However, some important issues need to be considered. The generalizability of the study may be limited, because the participants were primarily men. Therefore, conclusions from our study can be only applied to men, and it is possible that different patterns of cognitive impairment would emerge among women with a history of cerebrovascular disease. In addition, all participants had preexisting coronary heart disease and their initial inclusion in the BIP study required specific clinical characteristics. However, subjects with a high burden of vascular risk factors are at a higher risk of developing cognitive impairment. Overall we had an acceptable response rate of 86% among survivals. Nevertheless, because of the longtime duration between the baseline and T1 evaluation, a substantial proportion of individuals did not participate in the late-life assessment. Consequently, compared to individuals who did not participate in the late-life assessment, the study final subset of 558 surviving patients included healthier individuals. To account partly for the potential effect of survival bias, we analyzed the data also weighting by the inverse probability of inclusion at T1 and T2 follow-up evaluations. Additional limitation includes the absence of data on systematic brain imaging, and cognitive status at baseline.
In conclusion, we found a relationship between IR and poorer cognitive performance and cognitive decline among patients with cardiovascular disease. This association was found in the whole sample as well as among individuals without diabetes. Given these findings and since IR is a potentially modifiable midlife risk factor, it is intriguing to test the hypothesis that early intervention among high risk individuals with IR might deprive the negative consequences of IR on the brain.
